Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Epidermal cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    81 result(s) found for: Epidermal cells. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2018-002870-27 Sponsor Protocol Number: ASCAB Start Date*: 2018-12-11
    Sponsor Name:Dept. of Plastic Surgery and Burns Treatment, Copenhagen University Hospital Rigshospitalet
    Full Title: Adipose-derived Stem Cells in the treatment of Acute Burns (ASCAB)
    Medical condition: Skin burns.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10039798 Second degree burns LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004592-74 Sponsor Protocol Number: HOLOGENE7(HTA-HG7-01) Start Date*: 2016-06-01
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: PROSPECTIVE, OPEN LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETR...
    Medical condition: RDEB is characterized by generalized skin blistering, erosions, crusts, atrophic scarring, onychodystrophy and loss of nails, mutilating pseudosyndactyly of hands and feet, as well as oral cavity l...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000095-17 Sponsor Protocol Number: HOLOGENE17 Start Date*: 2017-08-17
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETR...
    Medical condition: JEB is genetically and clinically heterogeneous characterized by mutations in COL17A1,encoding for Collagen17 protein. COLXVII is a collagenous transmembrane type II protein component of the hemide...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000261-36 Sponsor Protocol Number: 1.0 Start Date*: 2021-01-27
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRINCULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED F...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000605-72 Sponsor Protocol Number: CB+MSCforEB Start Date*: 2014-02-06
    Sponsor Name:Universitair Medisch Centrum Utrecht
    Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa
    Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003972-12 Sponsor Protocol Number: CAEB071A2201 Start Date*: 2005-01-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2 week multiple ascending dose, double-blind placebo controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of twice daily administration of oral AEB071 and to explore th...
    Medical condition: moderate to severe chronic plaque psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    M15 10050576 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001952-32 Sponsor Protocol Number: ACA-NETH-07-14 Start Date*: 2008-11-07
    Sponsor Name:Radboud University Nijmegen Medical Centre - Department of Dermatology
    Full Title: The effect of adalimumab on immune markers in lesional psoriatic skin.
    Medical condition: Plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001780-27 Sponsor Protocol Number: HTA-HG5-04 Start Date*: Information not available in EudraCT
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: OPEN-LABEL, UNCONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF E...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient’s qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002425-21 Sponsor Protocol Number: 11054 Start Date*: 2012-02-10
    Sponsor Name:University of Nottingham
    Full Title: Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging
    Medical condition: Women having low ovarian reserve undergoing IVF/ICSI treatment
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006126-10 Sponsor Protocol Number: Efalizumab in CTCL Start Date*: 2008-11-27
    Sponsor Name:Charité - University Hospital Berlin
    Full Title: pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma
    Medical condition: The cutaneous T-cell lymphoma (also known as Sézary syndrome) is a common disorder of proliferated cells with characteristics of maligne t-lymphocytes immigrating from the cutaneous blood vessels t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001364-27 Sponsor Protocol Number: ZN-c5-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Zeno Alpha, Inc.,
    Full Title: A PHASE 1/2 OPEN LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ZN-C5 ALONE AND IN COMBINATION WITH PALBOCICLIB IN SUBJECTS WITH ESTROGEN-...
    Medical condition: Estrogen-receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) BG (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-000003-20 Sponsor Protocol Number: MEMPSOLAR0001 Start Date*: 2021-06-08
    Sponsor Name:Aarhus University Hospital
    Full Title: AN INVESTIGATOR INITIATED, PHASE 4, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTER STUDY INVESTIGATING THE RESIDUAL DISEASE MEMORY IN PSORIASIS SKIN DURING ENSTILAR® AND NARROW-BAND ULTRAVIOLET B THERAPY. ...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004500-30 Sponsor Protocol Number: ADSTEM001 Start Date*: 2015-02-13
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A phase I/II study evaluating allogeneic mesenchymal stromal cells in adults with recessive dystrophic epidermolysis bullosa
    Medical condition: Recessive dystrophic epidermolysis bullosa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000606-37 Sponsor Protocol Number: MesenSistem-EB Start Date*: 2017-11-16
    Sponsor Name:Fundación para la Investigación Biomédica Hospital Universitario La Paz
    Full Title: Safety and preliminary efficacy study of infusing mesenchymal stem cells derived from bone marrow for treating Recessive Dystrophic Epidermolysis Bullosa.
    Medical condition: Recessive Dystrophic Epidermolysis Bullosa
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000308-12 Sponsor Protocol Number: P150941J Start Date*: 2020-11-06
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Full Title: « Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial”
    Medical condition: Patients: Adults diagnosed with SJS-TEN with at least 10% of body surface area involved.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10025166 Lyell syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003300-31 Sponsor Protocol Number: 20159460(c) Start Date*: 2017-06-13
    Sponsor Name:Hellenic Society for the Study of Bone Metabolism
    Full Title: Evaluation of the efficacy of Denosumab in adult patients with Langerhans Cell Histiocytosis (LCH) : a multiple-site, single arm, open label Clinical Trial.
    Medical condition: Langerhans Cell Histiocytosis (LCH) is a rare disease of unknown etiology with variable clinical course exhibiting both neoplastic and inflammatory features. It is characterized by the accumulatio...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001197-24 Sponsor Protocol Number: D791AC00011 Start Date*: 2006-09-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced o...
    Medical condition: Non-small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003681-40 Sponsor Protocol Number: WO42633 Start Date*: 2021-03-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST C...
    Medical condition: Early human epidermal growth factor receptor 2 (HER2) positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004851-28 Sponsor Protocol Number: EVG001BC Start Date*: 2016-12-07
    Sponsor Name:Evgen Pharma PLC
    Full Title: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients with Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer...
    Medical condition: Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018614-70 Sponsor Protocol Number: D791AC00014 Start Date*: 2010-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Gr...
    Medical condition: Non Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025053 Lung cancer non-small cell stage IIIA LLT
    12.1 10025054 Lung cancer non-small cell stage IIIB LLT
    12.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) NO (Completed) HU (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 23:58:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA